Osmotic, controlled-release methylphenidate for the treatment of ADHD. (Q36613947)

15 August 2017

1 reference

title

Osmotic, controlled-release methylphenidate for the treatment of ADHD. (English)

1 reference

15 August 2017

David Coghill

1

1 reference

PubMed ID

17020437

15 August 2017

Sarah Seth

series ordinal

2

1 reference

PubMed ID

17020437

15 August 2017

language of work or name

English

0 references

publication date

1 October 2006

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

1 reference

15 August 2017

7

1 reference

15 August 2017

2119-2138

1 reference

15 August 2017

15

1 reference

NICE issues new guidelines on Ritalin

15 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

Medication and Hyperactivity: A Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

A systematic review of the associations between dose regimens and medication compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

Pemoline-associated fulminant liver failure: testing the evidence for causation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

Non-stimulant treatments for ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

Non-stimulant medications in the treatment of ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

21 January 2018

Stimulant medications

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

More frequent diagnosis of attention deficit-hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HCl in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

Effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR Food Evaluation (CAFE) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

European clinical guidelines for hyperkinetic disorder -- first upgrade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

Attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

Refining the diagnoses of inattention and overactivity syndromes: A reanalysis of the Multimodal Treatment study of attention deficit hyperactivity disorder (ADHD) based on ICD-10 criteria for hyperkinetic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.15.2119

10.1517/14656566.7.15.2119

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

17020437